Trial Profile
Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Biotin (Primary)
- Indications Multiple sclerosis; Optic neuritis
- Focus Registrational; Therapeutic Use
- Acronyms MS-ON
- Sponsors MedDay Pharmaceuticals
- 02 Apr 2022 This trial has been completed in France (Date of the global end of the trial : 01-Aug-2019), according to European Clinical Trials Database record.
- 28 May 2018 Results evaluating whether MD1003 improves vision compared with placebopublished in the CNS Drugs
- 23 Mar 2017 Planned End Date changed from 1 Jan 2016 to 1 Jan 2018.